VIDEO: UBX1325 improves vision in DME at 48 weeks in phase 2 study
SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Arshad M. Khanani, MD, MA, overviews the results of the phase 2 BEHOLD study investigating UBX1325 for the treatment of diabetic macular edema.
UBX1325 demonstrated improved visual acuity in patients with DME at 48 weeks compared with sham, which demonstrated essentially no improvement, according to Khanani.
“This novel mechanism of action is helping patients we all have in our clinic who have persistent disease activity despite frequent anti-VEGF injections,” he said.
Collapse
Khanani A. 48-week end of study results from BEHOLD phase 2 study of UBX1325 in patients with DME. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle.
Read more about